119436-52-1

Upstream product

• 6683-48-3 1,1,4,4,6-pentamethyl-1,2,3,4-tetrahydronaphthalene 
• 603-35-0 triphenylphosphine 
• 119435-90-4 (5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-bromomethane 

Downstream Products

• 119999-30-3 (Z)-4-<1-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-propenyl>benzenecarbonitrile 
• 119999-10-9 (E)-4-<1-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-propenyl>benzenecarbonitrile 
• 119436-53-2 methyl 4-((Z)-2-(1,2,3,4-tetrahydro-1,1,4,4-tetramethylnaphthalen-6-yl)vinyl)benzoate 
• 102121-54-0 Methyl (E)-4-<2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethenyl>benzoate 
• 326493-42-9 1,1,4,4-Tetramethyl-6-[(Z)-2-(4-nitro-phenyl)-vinyl]-1,2,3,4-tetrahydro-naphthalene 
• 119436-72-5 4-[(4S,5S)-2,2-Dimethyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-[1,3]dioxolan-4-yl]-benzoic acid methyl ester 
• 119436-73-6 4-[(4R,5S)-2,2-Dimethyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-[1,3]dioxolan-4-yl]-benzoic acid methyl ester 
• 119436-11-2 4-[(4S,5S)-2,2-Dimethyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-[1,3]dioxolan-4-yl]-benzoic acid 
• 119436-12-3 4-[(4R,5S)-2,2-Dimethyl-5-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-[1,3]dioxolan-4-yl]-benzoic acid 
• 119436-69-0 Methyl threo-4-<1,2-dihydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethyl>benzoate 
• 119436-70-3 Methyl erythro-4-<1,2-dihydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethyl>benzoate 
• 119436-08-7 threo-4-<1,2-Dihydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethyl>benzoic acid 
• 119436-09-8 erythro-4-<1,2-Dihydroxy-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)ethyl>benzoic acid 
• 119436-67-8 4-[3-(5,5,8,8-Tetramethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)-oxiranyl]-benzoic acid methyl ester 

Relevant academic research and scientific papers

Tricyclic hydroxamate and benzaminde derivatives, compositions and methods

The present invention relates to compounds and methods for inhibiting histone deacetylase enzymatic activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit histone deacetylases (HDACs), and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, and also central nervous system diseases. It further deals with processes for preparing said compounds.

Aromatic polycyclic retinoid-type derivatives, method for preparing same, and use thereof for making pharmaceutical and cosmetic compositions

Novel aromatic polycyclic retinoid-type derivatives of general formula (I), wherein groupings R3and R4attached to the double bond between carbons 11 and 12 are cis groupings, and pharmaceutical and cosmetic compositions containing same, are disclosed.

Retinobenzoic acids. 3. Structure-activity relationships of retinoidal azobenzene-4-carboxylic acids and stilbene-4-carboxylic acids

Alkyl-substituted azobenzene-4-carboxylic acids are potent differentiation inducers of human promyelocytic leukemia cell line HL-60 to mature granulocytes. Their structure-activity relationships are very similar to those of other retinoidal benzoic acids which are generally represented by 4 and named retinobenzoic acids. The structure-activity relationships of azobenzenecarboxylic acids can also be applied to the known retinoid TTNPB (3). Thus, (E)-4-[2-(3,4-diisopropylphenyl)-1-propenyl]benzoic acid (St30 (28)), and (E)-4-[2-(3-tert-butylphenyl)ethenyl]benzoic acid (St40) (29)), the acyclic alkyl analogues of TTNPB, are nearly as active as retinoic acid. Among the oxidatively derived compounds (Az90, Ep series and Ox series) of azobenzene- or stilbenecarboxylic acids, Az90 (71) and Ep80 (61) have strong activities. However, all the bishydroxylated derivatives of TTNPB are inactive, while a diketo analogue Ox580 (69) has only weak potency. The activities of conformationally restricted compounds of TTNPB offer some information on the stereochemistry of the active form of these retinoidal compounds.

Effect of structural modifications in the C7-C11 region of the retinoid skeleton on biological activity in a series of aromatic retinoids

A series of conformationally restricted analogues of (E)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)propent yl]benzoic acid - (E)-4-[1-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphtalenyl)-2-propt enyl]benzoic acid, (E)-4-[3-(5,6,7,8-tet